Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
NetherlandsIPO:
18 September 2014Website:
http://www.proqr.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 11 min agoDividend
Analysts recommendations
Institutional Ownership
PRQR Latest News
ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
PRQR, last year, failed a pivotal trial. This is the third time it has failed trials after showing early signs of efficacy. While they are making an effort, I see little future here.
ProQR (PRQR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.22 per share a year ago.
ProQR focuses on RNA cell-editing therapies to treat rare diseases. The company lost roughly $117 million in cash in 2022.
What type of business is ProQR Therapeutics NV?
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
What sector is ProQR Therapeutics NV in?
ProQR Therapeutics NV is in the Healthcare sector
What industry is ProQR Therapeutics NV in?
ProQR Therapeutics NV is in the Biotechnology industry
What country is ProQR Therapeutics NV from?
ProQR Therapeutics NV is headquartered in Netherlands
When did ProQR Therapeutics NV go public?
ProQR Therapeutics NV initial public offering (IPO) was on 18 September 2014
What is ProQR Therapeutics NV website?
https://www.proqr.com
Is ProQR Therapeutics NV in the S&P 500?
No, ProQR Therapeutics NV is not included in the S&P 500 index
Is ProQR Therapeutics NV in the NASDAQ 100?
No, ProQR Therapeutics NV is not included in the NASDAQ 100 index
Is ProQR Therapeutics NV in the Dow Jones?
No, ProQR Therapeutics NV is not included in the Dow Jones index
When was ProQR Therapeutics NV the previous earnings report?
No data
When does ProQR Therapeutics NV earnings report?
The next expected earnings date for ProQR Therapeutics NV is 02 August 2024